Welcome to Mondobiotech’s Investor Relations
mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE) is an independent Swiss biotech company discovering drugs for patients suffering from rare diseases through its proprietary Search & Match methodology.
In Search & Match mondobiotech’s scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering remedies for rare diseases to licensing partners.
The company has so far discovered more than 300 medicinal product candidates for further exploration in as many as possible of the 7000 rare diseases. Its products feature two major characteristics: being biologically active peptides of human origin and have platform potentiality for at least 3 orphan indications.
Investor Relations Contacts
Maria Teresa D'Antonangelo Bühlmann
mondoBIOTECH holding AG
Investor & External Relations
Mürgstrasse 18
CH-6370 Stans
Switzerland
T. +41 (0)840 200 010
F. +41 (0)840 200 011
investor@mondobiotech.com
Company Presentation
Development Pipeline
Fact Sheet
Stock InformationLatest News
mondoBIOTECH holding AG’s (SIX:RARE) Board of Directors nominates the Chairman and Vice-Chairman and the members of the Executive Committee
mondoBIOTECH holding AG (SIX:RARE) announces the results of its Annual General Meeting and re-elections in the Board of Directors
mondoBIOTECH holding AG announces changes in the composition of the Board of Directors
mondoBIOTECH and Pierrel agree to stop negotiations for a business combination
mondoBIOTECH holding AG (SIX: RARE) published today the invitation to its 5th ordinary shareholders' meeting and announced its financial results for 2011 as well as the candidates for election to its Board of Directors.
- Mondobiotech
- Fast fact
- Overview
- Milestones
- Board of Directors
- Management
- Location
- Products
- Product Overview
- Types of products
- Pipeline
- Rare Diseases
- About Rare Diseases
- Patient and Families
- Rare Diseases List
- Media Archive
- Investor
- Financial Information
- Key Information
- Corporate Governance
- Appointments
- Partnership
- Pipeline
- Science
- Pipeline
- Product Overview
- Research Vision